STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.

Criteria

Inclusion Criteria

• Males and females 18 years or older

• Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol

• Must have acceptable organ function during screening as defined in the protocol

Exclusion Criteria

• Pregnant or breast-feeding women

• Patients must meet the washout periods for prior chemotherapies and radiation

• History of stroke within 6 months of treatment

• Poor venous access for study drug administration

• Treatment with chronic immunosuppressants

• Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation